Hyper Personalized Medicine Market By Product (Hyper Personalized Medicine Diagnostics, Hyper Personalized Medicine Therapeutics, Hyper Personalized Medical Care, Hyper Personalized Nutrition and Wellness), By Application (Oncology, Neurology, Blood Transfusion Safety, Diabetes, Autoimmune Diseases, Cardiology), By End User (Hospitals, Diagnostic Centers, Research and Academic Institutes, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Hyper Personalized Medicine Market

Hyper personalized medicine is a distinct approach that refers to personalizing medical treatment to the unique characteristics of patients. Precision medicine is another term for personalized medicine. These medicines are created using the genetic configuration of the human genome. It has become the primary concern for the diagnosis, prevention, and treatment of any disease, and customized medicine is founded on pharmacogenomics and genomics. The improvement of molecular profile technology to gain access to RNA, DNA, and protein will enhance tailored therapy for illness management. Precision medicine has several advantages over conventional medicine, including optimum therapy, increased safety and efficacy, fewer adverse drug reactions, improved patient compliance, and reduced cost, time, and clinical trial failure rate.

Hyper personalized medicine examines the patient's characteristics, DNA, and proteins to build a personalized therapeutic pill to address the specific condition. Personalized medicine is predicted to grow in the upcoming years due to substantial developments in precision medicine, such as single nucleotide polymorphism and microarray/b ochips. The development of effective treatments for individual patients' diseases based on an understanding of their genetic makeup, molecular profiles, and clinical characteristics is made possible by human genome research. The factors mentioned above are expected to boost the demand for precision medicine in the future. Apart from that, rise in the prevalence of cancer is expected to increase demand for hyper personalized medicine for personalized therapeutics and diagnostics, which will have a positive impact on market growth.

Hyper personalized medicine applications are primarily aimed at improving the treatment of oncological diseases and are expected to grow significantly during the forecast period.The majority of companies offering personalized medicine solutions have restricted their operations to developed markets, leaving the enormous potential of emerging markets untapped. With their huge population and high risk of diseases (whose treatment necessitates gene sequencing), countries like China, India, Australia,  and South Africa present a significant opportunity for the growth of the hyper personalized medicine business. The future of hyper personalized medicine seems bright, with various prospects developing in the industry. Hyper personalized medicine is anticipated to advance owing to the growing use of artificial intelligence and machine learning in healthcare, as well as the accessibility of big data. In addition, the introduction of telemedicine and the growing tendency towards remote patient monitoring is likely to further boost the growth of this market. Also, the growing emphasis on precision medicine and companion diagnostics is projected to generate major prospects for hyper personalized medicine in the future.

The hyper personalized medicine market is segmented into product, application, end user, and region. By product, the market is classified into hyper personalized medicine diagnostics, hyper personalized medicine therapeutics, hyper personalized medical care, and hyper personalized nutrition & wellness. As per application, it is divided into oncology, neurology, blood transfusion safety, diabetes, autoimmune diseases, and cardiology. On the basis of end user, the market is divided into hospitals, diagnostic centers, research & academic institutes, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, United Arab Emirates, South Africa, and rest of LAMEA).

The key players profiled in the study include QIAGEN, Exagen Inc., Abbott, Dako A/S, GE Healthcare, Illumina, Inc., ASURAGEN, INC., Exact Sciences Corporation, Danaher Corporation (Cepheid, Inc.), and Decode Genetics, Inc. The key players in the market have been actively engaged in the adoption of various strategies such as acquisition, product launches, and expansion to remain competitive and gain an advantage over the competitors in the market. For instance, in January 2022, Panaceutics Nutrition and Viocare announced a collaboration agreement to create personalized nutrition for healthcare providers and their subjects through the use of a high-end technology interface by integrating Viocare's nutrition assessment software with personalized nutrition supplementation to create an end-to-end service platform.

Key Market Insights

Based on product, the hyper personalized nutrition and wellness sub-segment accounted for a dominant position in 2021 and the hyper personalized medicine therapeutics sub-segment is anticipated to be the fastest growing during the forecast period

Based on application, the oncology sub-segment accounted for the dominant market share in 2021 and is anticipated to be the fastest growing during the forecast period

Based on end user, the hospitals sub-segment accounted for a dominant market share in 2021 the and residential sub-segment is expected to grow significantly in the upcoming years

Based on region, North America accounted for the dominant market share in 2021 and is projected to account for a significant growth rate during the forecast period

Overview

The global hyper personalized medicine market is anticipated to reach $5.9 trillion by 2031, growing from $2.1 trillion in 2021 at a CAGR of 11.7% from 2022 to 2031.

The development of patient-specific, targeted, and customized treatments offered to people based on more than just a diagnosis is known as hyper personalized medicine. Hyper personalized medicine has the ability to identify rare and potentially life-threatening conditions well in advance of the manifestation of any symptoms through DNA screening. Essentially, this means that these advanced medical techniques not only treat diseases but also help in the prevention of disease susceptibility.

Hyper personalized medicine methods are in high demand worldwide owing to the increase in the prevalence of cancer and the growing number of treatment candidates in clinical trials. Furthermore, the increase in the incidence of genetic diseases is projected to have a significant impact on the growth of the hyper personalized medicine market. The recent advancement in technologies such as ultra-high throughput sequencing and next-generation sequencing is another significant factor that is projected to drive the hyper personalized medicine market growth rate.

The high cost of developing and implementing these advanced medical technologies is one of the primary limitations in the hyper personalized medicine market. This can make them inaccessible to certain sectors of the population, notably those with minimal financial resources or living in areas with inadequate healthcare facilities. Also, there may be worries about patient data privacy and security, which can have an impact on the adoption of hyper personalized medicine.

Growing incidences of respiratory diseases, rapid technological advancements in healthcare, and an aging population are driving the hyper personalized medicine market growth. Furthermore, an increase in the use of therapeutic respiratory devices such as nebulizers, oxygen concentrators, and humidifiers is projected to drive the industry expansion. According to WHO projections, 3.2 million people died worldwide in 2019 from mild to severe Chronic Obstructive Pulmonary Disease (COPD). Furthermore, according to WHO projections, COPD will be the third leading cause of death globally. An increase in the adoption of emerging genomic technologies such as next-generation sequencing (NGS) and high-density microarray, along with favorable government initiatives, is expected to boost the global gene therapy market and, as a result, the hyper personalized medicine market.

The COVID-19 pandemic had an impact on the market for hyper personalized medicine. The market for hyper personalized medicine has seen a modest influence from the COVID-19 pandemic. COVID-19 has raised the demand for customized medicine solutions as patients and healthcare professionals seek more tailored COVID-19 therapies and diagnostics. This has resulted in an increase in R&D of personalized medicine approaches to COVID-19, such as the development of vaccinations that can be customized to individual immune systems. The hyper personalized medicine market involves the application of cutting-edge technologies such as genomics, proteomics, and digital health to tailor medical treatments to individual individuals based on their genetic makeup, lifestyle, and health history. This strategy seeks to enhance patient outcomes while lowering healthcare expenses. The pandemic has disrupted supply chains, hindered clinical trials, and lowered healthcare budgets, all of which have the potential to limit the expansion of the hyper personalized medicine market.

The key players profiled in this report include QIAGEN, Exagen Inc., Abbott, Dako A/S, GE Healthcare, Illumina, Inc., ASURAGEN, INC., Exact Sciences Corporation, Danaher Corporation (Cepheid, Inc.), and Decode Genetics, Inc.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyper personalized medicine market analysis from 2021 to 2031 to identify the prevailing hyper personalized medicine market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the hyper personalized medicine market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global hyper personalized medicine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Decode Genetics, Inc

Scope of Hyper Personalized Medicine Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.4. Market dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.5. COVID-19 Impact Analysis on the market

3.6. Average Selling Price

3.7. Brand Share Analysis

3.8. Key Regulation Analysis

3.9. Market Share Analysis

3.10. Patent Landscape

3.11. Regulatory Guidelines

3.12. Value Chain Analysis

4.1. Overview

4.1.1. Market size and forecast

4.2. Hyper Personalized Medicine Diagnostics

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Hyper Personalized Medicine Therapeutics

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Hyper Personalized Medical Care

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Hyper Personalized Nutrition and Wellness

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Oncology

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Neurology

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Blood Transfusion Safety

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.5. Diabetes

5.5.1. Key market trends, growth factors and opportunities

5.5.2. Market size and forecast, by region

5.5.3. Market share analysis by country

5.6. Autoimmune Diseases

5.6.1. Key market trends, growth factors and opportunities

5.6.2. Market size and forecast, by region

5.6.3. Market share analysis by country

5.7. Cardiology

5.7.1. Key market trends, growth factors and opportunities

5.7.2. Market size and forecast, by region

5.7.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Diagnostic Centers

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Research and Academic Institutes

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

6.5. Others

6.5.1. Key market trends, growth factors and opportunities

6.5.2. Market size and forecast, by region

6.5.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Product

7.2.3. Market size and forecast, by Application

7.2.4. Market size and forecast, by End User

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Product

7.2.5.1.3. Market size and forecast, by Application

7.2.5.1.4. Market size and forecast, by End User

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Product

7.2.5.2.3. Market size and forecast, by Application

7.2.5.2.4. Market size and forecast, by End User

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Product

7.2.5.3.3. Market size and forecast, by Application

7.2.5.3.4. Market size and forecast, by End User

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Product

7.3.3. Market size and forecast, by Application

7.3.4. Market size and forecast, by End User

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Product

7.3.5.1.3. Market size and forecast, by Application

7.3.5.1.4. Market size and forecast, by End User

7.3.5.2. UK

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Product

7.3.5.2.3. Market size and forecast, by Application

7.3.5.2.4. Market size and forecast, by End User

7.3.5.3. France

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Product

7.3.5.3.3. Market size and forecast, by Application

7.3.5.3.4. Market size and forecast, by End User

7.3.5.4. Spain

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Product

7.3.5.4.3. Market size and forecast, by Application

7.3.5.4.4. Market size and forecast, by End User

7.3.5.5. Italy

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Product

7.3.5.5.3. Market size and forecast, by Application

7.3.5.5.4. Market size and forecast, by End User

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Product

7.3.5.6.3. Market size and forecast, by Application

7.3.5.6.4. Market size and forecast, by End User

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Product

7.4.3. Market size and forecast, by Application

7.4.4. Market size and forecast, by End User

7.4.5. Market size and forecast, by country

7.4.5.1. China

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Product

7.4.5.1.3. Market size and forecast, by Application

7.4.5.1.4. Market size and forecast, by End User

7.4.5.2. Japan

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Product

7.4.5.2.3. Market size and forecast, by Application

7.4.5.2.4. Market size and forecast, by End User

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Product

7.4.5.3.3. Market size and forecast, by Application

7.4.5.3.4. Market size and forecast, by End User

7.4.5.4. South Korea

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Product

7.4.5.4.3. Market size and forecast, by Application

7.4.5.4.4. Market size and forecast, by End User

7.4.5.5. Australia

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Product

7.4.5.5.3. Market size and forecast, by Application

7.4.5.5.4. Market size and forecast, by End User

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Product

7.4.5.6.3. Market size and forecast, by Application

7.4.5.6.4. Market size and forecast, by End User

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Product

7.5.3. Market size and forecast, by Application

7.5.4. Market size and forecast, by End User

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Product

7.5.5.1.3. Market size and forecast, by Application

7.5.5.1.4. Market size and forecast, by End User

7.5.5.2. United Arab Emirates

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Product

7.5.5.2.3. Market size and forecast, by Application

7.5.5.2.4. Market size and forecast, by End User

7.5.5.3. Saudi Arabia

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Product

7.5.5.3.3. Market size and forecast, by Application

7.5.5.3.4. Market size and forecast, by End User

7.5.5.4. South Africa

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Product

7.5.5.4.3. Market size and forecast, by Application

7.5.5.4.4. Market size and forecast, by End User

7.5.5.5. Rest of LAMEA

7.5.5.5.1. Key market trends, growth factors and opportunities

7.5.5.5.2. Market size and forecast, by Product

7.5.5.5.3. Market size and forecast, by Application

7.5.5.5.4. Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2021

9.1. Abbott

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.2. Dako A/S

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.3. GE Healthcare

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.4. Illumina, Inc.

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.5. ASURAGEN, INC.

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.6. Exact Sciences Corporation

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.7. Danaher Corporation (Cepheid, Inc.)

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.8. Decode Genetics, Inc.

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.9. QIAGEN

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.10. Exagen Inc.

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapsho

LIST OF TABLES

TABLE 01. GLOBAL HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 02. HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED MEDICINE DIAGNOSTICS, BY REGION, 2021-2031 ($BILLION)

TABLE 03. HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED MEDICINE THERAPEUTICS, BY REGION, 2021-2031 ($BILLION)

TABLE 04. HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED MEDICAL CARE, BY REGION, 2021-2031 ($BILLION)

TABLE 05. HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED NUTRITION AND WELLNESS, BY REGION, 2021-2031 ($BILLION)

TABLE 06. GLOBAL HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 07. HYPER PERSONALIZED MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021-2031 ($BILLION)

TABLE 08. HYPER PERSONALIZED MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2021-2031 ($BILLION)

TABLE 09. HYPER PERSONALIZED MEDICINE MARKET FOR BLOOD TRANSFUSION SAFETY, BY REGION, 2021-2031 ($BILLION)

TABLE 10. HYPER PERSONALIZED MEDICINE MARKET FOR DIABETES, BY REGION, 2021-2031 ($BILLION)

TABLE 11. HYPER PERSONALIZED MEDICINE MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021-2031 ($BILLION)

TABLE 12. HYPER PERSONALIZED MEDICINE MARKET FOR CARDIOLOGY, BY REGION, 2021-2031 ($BILLION)

TABLE 13. GLOBAL HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 14. HYPER PERSONALIZED MEDICINE MARKET FOR HOSPITALS, BY REGION, 2021-2031 ($BILLION)

TABLE 15. HYPER PERSONALIZED MEDICINE MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 ($BILLION)

TABLE 16. HYPER PERSONALIZED MEDICINE MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2021-2031 ($BILLION)

TABLE 17. HYPER PERSONALIZED MEDICINE MARKET FOR OTHERS, BY REGION, 2021-2031 ($BILLION)

TABLE 18. HYPER PERSONALIZED MEDICINE MARKET, BY REGION, 2021-2031 ($BILLION)

TABLE 19. NORTH AMERICA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 20. NORTH AMERICA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 21. NORTH AMERICA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 22. NORTH AMERICA HYPER PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)

TABLE 23. U.S. HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 24. U.S. HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 25. U.S. HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 26. CANADA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 27. CANADA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 28. CANADA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 29. MEXICO HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 30. MEXICO HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 31. MEXICO HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 32. EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 33. EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 34. EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 35. EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)

TABLE 36. GERMANY HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 37. GERMANY HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 38. GERMANY HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 39. UK HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 40. UK HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 41. UK HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 42. FRANCE HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 43. FRANCE HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 44. FRANCE HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 45. SPAIN HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 46. SPAIN HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 47. SPAIN HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 48. ITALY HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 49. ITALY HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 50. ITALY HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 51. REST OF EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 52. REST OF EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 53. REST OF EUROPE HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 54. ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 55. ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 56. ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 57. ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)

TABLE 58. CHINA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 59. CHINA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 60. CHINA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 61. JAPAN HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 62. JAPAN HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 63. JAPAN HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 64. INDIA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 65. INDIA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 66. INDIA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 67. SOUTH KOREA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 68. SOUTH KOREA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 69. SOUTH KOREA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 70. AUSTRALIA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 71. AUSTRALIA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 72. AUSTRALIA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 73. REST OF ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 74. REST OF ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 75. REST OF ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 76. LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 77. LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 78. LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 79. LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)

TABLE 80. BRAZIL HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 81. BRAZIL HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 82. BRAZIL HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 83. UNITED ARAB EMIRATES HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 84. UNITED ARAB EMIRATES HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 85. UNITED ARAB EMIRATES HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 86. SAUDI ARABIA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 87. SAUDI ARABIA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 88. SAUDI ARABIA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 89. SOUTH AFRICA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 90. SOUTH AFRICA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 91. SOUTH AFRICA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 92. REST OF LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 93. REST OF LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 94. REST OF LAMEA HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 95. ABBOTT: KEY EXECUTIVES

TABLE 96. ABBOTT: COMPANY SNAPSHOT

TABLE 97. DAKO A/S: KEY EXECUTIVES

TABLE 98. DAKO A/S: COMPANY SNAPSHOT

TABLE 99. GE HEALTHCARE: KEY EXECUTIVES

TABLE 100. GE HEALTHCARE: COMPANY SNAPSHOT

TABLE 101. ILLUMINA, INC.: KEY EXECUTIVES

TABLE 102. ILLUMINA, INC.: COMPANY SNAPSHOT

TABLE 103. ASURAGEN, INC.: KEY EXECUTIVES

TABLE 104. ASURAGEN, INC.: COMPANY SNAPSHOT

TABLE 105. EXACT SCIENCES CORPORATION: KEY EXECUTIVES

TABLE 106. EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT

TABLE 107. DANAHER CORPORATION (CEPHEID, INC.): KEY EXECUTIVES

TABLE 108. DANAHER CORPORATION (CEPHEID, INC.): COMPANY SNAPSHOT

TABLE 109. DECODE GENETICS, INC.: KEY EXECUTIVES

TABLE 110. DECODE GENETICS, INC.: COMPANY SNAPSHOT

TABLE 111. QIAGEN: KEY EXECUTIVES

TABLE 112. QIAGEN: COMPANY SNAPSHOT

TABLE 113. EXAGEN INC.: KEY EXECUTIVES

TABLE 114. EXAGEN INC.: COMPANY SNAPSHOT LIST OF FIGURES

FIGURE 01. HYPER PERSONALIZED MEDICINE MARKET, 2021-2031

FIGURE 02. SEGMENTATION OF HYPER PERSONALIZED MEDICINE MARKET, 2021-2031

FIGURE 03. TOP INVESTMENT POCKETS IN HYPER PERSONALIZED MEDICINE MARKET (2022-2031)

FIGURE 04. PORTER FIVE-1

FIGURE 05. PORTER FIVE-2

FIGURE 06. PORTER FIVE-3

FIGURE 07. PORTER FIVE-4

FIGURE 08. PORTER FIVE-5

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALHYPER PERSONALIZED MEDICINE MARKET

FIGURE 10. IMPACT OF KEY REGULATION: HYPER PERSONALIZED MEDICINE MARKET

FIGURE 11. MARKET SHARE ANALYSIS: HYPER PERSONALIZED MEDICINE MARKET

FIGURE 12. PATENT ANALYSIS BY COMPANY

FIGURE 13. PATENT ANALYSIS BY COUNTRY

FIGURE 14. REGULATORY GUIDELINES: HYPER PERSONALIZED MEDICINE MARKET

FIGURE 15. VALUE CHAIN ANALYSIS: HYPER PERSONALIZED MEDICINE MARKET

FIGURE 16. HYPER PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED MEDICINE DIAGNOSTICS, BY COUNTRY 2021 AND 2031(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED MEDICINE THERAPEUTICS, BY COUNTRY 2021 AND 2031(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED MEDICAL CARE, BY COUNTRY 2021 AND 2031(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR HYPER PERSONALIZED NUTRITION AND WELLNESS, BY COUNTRY 2021 AND 2031(%)

FIGURE 21. HYPER PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY 2021 AND 2031(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY 2021 AND 2031(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR BLOOD TRANSFUSION SAFETY, BY COUNTRY 2021 AND 2031(%)

FIGURE 25. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR DIABETES, BY COUNTRY 2021 AND 2031(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY 2021 AND 2031(%)

FIGURE 27. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR CARDIOLOGY, BY COUNTRY 2021 AND 2031(%)

FIGURE 28. HYPER PERSONALIZED MEDICINE MARKET, BY END USER, 2021(%)

FIGURE 29. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR HOSPITALS, BY COUNTRY 2021 AND 2031(%)

FIGURE 30. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY 2021 AND 2031(%)

FIGURE 31. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY 2021 AND 2031(%)

FIGURE 32. COMPARATIVE SHARE ANALYSIS OF HYPER PERSONALIZED MEDICINE MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)

FIGURE 33. HYPER PERSONALIZED MEDICINE MARKET BY REGION, 2021

FIGURE 34. U.S. HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 35. CANADA HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 36. MEXICO HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 37. GERMANY HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 38. UK HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 39. FRANCE HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 40. SPAIN HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 41. ITALY HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 42. REST OF EUROPE HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 43. CHINA HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 44. JAPAN HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 45. INDIA HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 46. SOUTH KOREA HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 47. AUSTRALIA HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 48. REST OF ASIA-PACIFIC HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 49. BRAZIL HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 50. UNITED ARAB EMIRATES HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 51. SAUDI ARABIA HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 52. SOUTH AFRICA HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 53. REST OF LAMEA HYPER PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 54. TOP WINNING STRATEGIES, BY YEAR

FIGURE 55. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 56. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 57. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 58. COMPETITIVE DASHBOARD

FIGURE 59. COMPETITIVE HEATMAP: HYPER PERSONALIZED MEDICINE MARKET

FIGURE 60. TOP PLAYER POSITIONING, 202